ABivax SA: Shares up 2.8% after GS initiates at 'buy'

Abivax

Goldman Sachs

ABivax SA: Shares up 2.8% after GS initiates at 'buy'

Goldman Sachs has initiated coverage on Abivax SA (ABVX) with a "Buy" rating, aligning with the broader analyst consensus. As of September 10, 2026, 12 analysts have evaluated the stock, with 33% recommending a "Strong Buy," 58% a "Buy," and 8% suggesting a "Hold," while <a href="https://www.google.com/goto?url=CAESbAHrOzAVWuJUiUEYhIrfbM8xWIU63LF76QHw-QDYkDgBbJS9DMUUcaglRFGsTAfWhxcOXR1fQd3C4MTv6Pn5jcTKZqGo2Ul0UGNdd7Qlsb8KtJyBIGDbxGfr39L9qp-ZYN6z3IBH6moXxbgybg">no analysts have issued "Sell"</a> or "Strong Sell" ratings. The firm's decision reflects confidence in Abivax's drug development pipeline, particularly its candidate obefazimod for ulcerative colitis, which has <a href="https://www.google.com/goto?url=CAESbAHrOzAVWuJUiUEYhIrfbM8xWIU63LF76QHw-QDYkDgBbJS9DMUUcaglRFGsTAfWhxcOXR1fQd3C4MTv6Pn5jcTKZqGo2Ul0UGNdd7Qlsb8KtJyBIGDbxGfr39L9qp-ZYN6z3IBH6moXxbgybg">positive outcomes in multiple Phase 3</a> trials. However, the drug has also drawn attention due to <a href="https://www.google.com/goto?url=CAESbAHrOzAVWuJUiUEYhIrfbM8xWIU63LF76QHw-QDYkDgBbJS9DMUUcaglRFGsTAfWhxcOXR1fQd3C4MTv6Pn5jcTKZqGo2Ul0UGNdd7Qlsb8KtJyBIGDbxGfr39L9qp-ZYN6z3IBH6moXxbgybg">higher incidence of adverse events</a> at the 50mg dose, raising questions about its long-term safety profile. Despite these concerns, the <a href="https://www.google.com/goto?url=CAESbAHrOzAVWuJUiUEYhIrfbM8xWIU63LF76QHw-QDYkDgBbJS9DMUUcaglRFGsTAfWhxcOXR1fQd3C4MTv6Pn5jcTKZqGo2Ul0UGNdd7Qlsb8KtJyBIGDbxGfr39L9qp-ZYN6z3IBH6moXxbgybg">malignancy and non-malignant cancer (NMC) rates</a> remain within expected ranges for the ulcerative colitis patient population. Analysts have set <a href="https://www.google.com/goto?url=CAESbAHrOzAVWuJUiUEYhIrfbM8xWIU63LF76QHw-QDYkDgBbJS9DMUUcaglRFGsTAfWhxcOXR1fQd3C4MTv6Pn5jcTKZqGo2Ul0UGNdd7Qlsb8KtJyBIGDbxGfr39L9qp-ZYN6z3IBH6moXxbgybg">a price target of $152.33</a>, indicating no immediate change from the current stock price. Investors are advised to consider these factors alongside their own risk tolerance and investment strategy.<img src="https://cdn.ainvest.com/aigc/hxcmp/images/compress-1d1d5ced474db001.png" alt="ABivax SA: Goldman Sachs initiates coverage with buy rating">

ABivax SA: Goldman Sachs initiates coverage with buy rating

Abivax SA Sponsored ADR (ABVX) has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in earnings estimates. The change in earnings potential, as reflected in earnings estimate revisions, is strongly correlated with near-term price movements. Institutional investors use earnings estimates to calculate fair value, which can lead to increased buying pressure and stock price growth. The upgrade reflects positivity about Abivax SA Sponsored ADR's earnings outlook, translating into buying pressure and higher stock prices.

Abivax SA Upgraded to Buy on Strong Earnings Estimates

Based on the 15-minute chart analysis, Abivax's recent price movement has triggered a narrowing of Bollinger Bands and a bearish Marubozu at 09/04/2026 13:45. This indicates a decrease in the magnitude of stock price fluctuations, which suggests that sellers are currently in control of the market. Furthermore, the bearish momentum is likely to persist, which may indicate a continuation of the downward trend.Abivax SA (ABVX) has shown bearish signals on the 15-minute chart, with a narrowing of Bollinger Bands and a bearish Marubozu candle forming at 09/04/2026 13:45. This pattern suggests a reduction in price volatility and indicates that <a href="https://www.investing.com/equities/abivax-sa-candlestick">sellers are currently dominating the market</a>. The bearish Marubozu, characterized by a long lower shadow and no upper shadow, reinforces the downward pressure on the stock price and may <a href="https://www.investing.com/equities/abivax-sa-candlestick">signal a continuation of the</a> current bearish trend.Technical indicators further support this bearish outlook. The stock price remains below its 5, 20, and 50-day exponential moving averages, <a href="https://financhill.com/stock-price-chart/abvx-technical-analysis">reinforcing a strongly bearish trend</a>. Additionally, the 8-day, 20-day, and 50-day simple and exponential moving averages all <a href="https://financhill.com/stock-price-chart/abvx-technical-analysis">indicate sell signals</a>, with the stock trading below these levels. The MACD (12, 26) stands at -3.28, and the RSI is at 42.08, both of which <a href="https://financhill.com/stock-price-chart/abvx-technical-analysis">suggest bearish momentum</a>.The Bollinger Bands (25) currently range between 114.41 and 125.87, with the stock price near the lower boundary, <a href="https://financhill.com/stock-price-chart/abvx-technical-analysis">indicating potential for further downward movement</a>. While the 200-day simple moving average (119.40) and the 200-day exponential moving average (110.32) remain in sell and buy territory respectively, the overall technical indicators suggest <a href="https://financhill.com/stock-price-chart/abvx-technical-analysis">a continuation of the bearish trend</a>.Investors should monitor the stock closely for signs of a breakout or reversal, particularly as the Bollinger Bands continue to contract. A sustained move above the upper band or a strong bullish candlestick pattern could signal a shift in momentum. However, based on the current technical setup, the likelihood of further downward movement remains elevated.

Abivax's 15min chart shows Bollinger Bands narrowing, bearish Marubozu formation.

As per the 15-minute chart analysis, Abivax's price movement has triggered Bollinger Bands Narrowing, accompanied by a KDJ Death Cross at 09/03/2026 15:45. This indicates a decrease in the magnitude of stock price fluctuations and a shift in momentum towards the downside, which may lead to further decreases in the stock price.Recent technical analysis of Abivax's stock price on the 15-minute chart has identified key indicators of potential downward momentum. At 15:45 on September 3, 2026, the stock exhibited Bollinger Bands narrowing, a pattern often associated with reduced volatility and a potential breakout or breakdown in price movement. Concurrently, a KDJ Death Cross was observed, signaling <a href="https://www.investopedia.com/terms/d/deathcross.asp">a shift in momentum</a> toward the downside. This combination suggests that the stock may experience further price declines in the near term.Abivax’s recent performance, including a closing price of $105.90 on August 17, 2026, with <a href="https://ir.abivax.com/stock-information/historic-price-lookup">a trading volume of 121,638 shares</a>, provides context for the current technical indicators. While historical data shows that death crosses are not always predictive of long-term bear markets, they often <a href="https://www.investopedia.com/terms/d/deathcross.asp">coincide with short-term market corrections</a> or shifts in investor sentiment. Investors are advised to monitor these signals closely, as they may influence short-term trading strategies and risk management decisions.

ABVX News